The EXPrESSIVE-10 study (MK-8527-010) is a Phase 3 clinical trial evaluating an investigational, once-monthly oral pill (MK-8527) for HIV pre-exposure prophylaxis (PrEP) in roughly 4,580 adolescent girls and young women aged 16–30 in Kenya, South Africa, and Uganda. It compares the efficacy and safety of this long-acting pill against daily oral PrEP (TDF/FTC) to provide a more discreet and manageable prevention option. 

Register here to participate in the study

Scan the QR code below.